Recent advances in the treatment of cystinosis
dc.contributor.author | Schneider, Jerry A. | en_US |
dc.contributor.author | Clark, K. F. | en_US |
dc.contributor.author | Greene, A. A. | en_US |
dc.contributor.author | Reisch, J. S. | en_US |
dc.contributor.author | Markello, T. C. | en_US |
dc.contributor.author | Gahl, William A. | en_US |
dc.contributor.author | Thoene, Jess G. | en_US |
dc.contributor.author | Noonan, P. K. | en_US |
dc.contributor.author | Berry, K. A. | en_US |
dc.date.accessioned | 2006-09-08T20:24:23Z | |
dc.date.available | 2006-09-08T20:24:23Z | |
dc.date.issued | 1995-07 | en_US |
dc.identifier.citation | Schneider, J. A.; Clark, K. F.; Greene, A. A.; Reisch, J. S.; Markello, T. C.; Gahl, W. A.; Thoene, J. G.; Noonan, P. K.; Berry, K. A.; (1995). "Recent advances in the treatment of cystinosis." Journal of Inherited Metabolic Disease 18(4): 387-397. <http://hdl.handle.net/2027.42/42499> | en_US |
dc.identifier.issn | 0141-8955 | en_US |
dc.identifier.issn | 1573-2665 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/42499 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=7494398&dopt=citation | en_US |
dc.description.abstract | Cysteamine bitartrate capsules (Cystagon) have been approved by the US Food and Drug Administration for use in patients with nephropathic cystinosis. Plasma cysteamine concentrations were virtually identical at various times following ingestion of either cysteamine hydrochloride or Cystagon capsules in 24 normal control subjects. A transfer study was done with eight cystinosis patients who had been receiving either cysteamine hydrochloride or phosphocysteamine for many years. The plasma cysteamine concentration was significantly higher 2h after Cystagon and the leukocyte cystine content was significantly lower at all times after Cystagon compared to older forms of the drug. These differences are probably the result of greater patient compliance in taking the capsules compared to the older, liquid forms of the drug. A new method for following the course of renal glomerular deterioration in diseases such as cystinosis has been published recently. This method was used to re-analyse data on the efficacy of cysteamine treatment and to re-analyse new data on treating cystinosis patients with either of two doses of cysteamine (1.30 g/m 2 per day and 1.95 g/m 2 per day). This new method agrees well with other methods and shows that both doses of drug are equally effective in maintaining glomerular function. | en_US |
dc.format.extent | 659793 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers; Society for the Study of Inborn Errors of Metabolism and Kluwer Academic Publishers ; Springer Science+Business Media | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Internal Medicine | en_US |
dc.subject.other | Medical Biochemistry | en_US |
dc.subject.other | Pediatrics | en_US |
dc.title | Recent advances in the treatment of cystinosis | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Kinesiology and Sports | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | Division of Pediatric Metabolism, Department of Pediatrics, University of California San Diego, 9500 Gilman Drive DEPT 0609 F, 92093-0609, La Jolla, CA, USA | en_US |
dc.contributor.affiliationother | Division of Pediatric Metabolism, Department of Pediatrics, University of California San Diego, 9500 Gilman Drive DEPT 0609 F, 92093-0609, La Jolla, CA, USA | en_US |
dc.contributor.affiliationother | Division of Pediatric Metabolism, Department of Pediatrics, University of California San Diego, 9500 Gilman Drive DEPT 0609 F, 92093-0609, La Jolla, CA, USA | en_US |
dc.contributor.affiliationother | University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA | en_US |
dc.contributor.affiliationother | National Institute of Child and Human Development, Bethesda, Maryland, USA; Medical College of Virginia, Richman, Virginia, USA | en_US |
dc.contributor.affiliationother | National Institute of Child and Human Development, Bethesda, Maryland, USA | en_US |
dc.contributor.affiliationother | Mylan Pharmaceuticals, Inc., Morgantown, West Virginia, USA | en_US |
dc.contributor.affiliationother | Mylan Pharmaceuticals, Inc., Morgantown, West Virginia, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 7494398 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/42499/1/10545_2004_Article_BF00710051.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00710051 | en_US |
dc.identifier.source | Journal of Inherited Metabolic Disease | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.